Floatz logo

P-Psma-101 Car-T Cells

Neoplasms, Prostate

Poseida Therapeutics, Inc.Cell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

514 Active assets in the Neoplasms, Prostate cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

P-Psma-101 Car-T Cells is also rated in:

adenoid cystic carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
urinary system neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
male reproductive system neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →